通常取引データ（自動更新なし）RVOL 0.2xDV $6M20日平均DV $26M?
Earnings 2026-11-0952W high -21.1%52W low +95.7%Fwd PER 42.8xMarket cap $2.0BAvg volume 1.8M
Company Overview
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | -0.91 | $0 | -$86M |
| 2026 Q1 | -0.88 | $0 | -$150M |
| 2025 Q4 | -1.21 | $0 | -$131M |
| 2025 Q3 | -1.64 | $0 | -$146M |
| 2025 Q2 | -1.94 | $0 | -$168M |
| 2025 Q1 | -2.17 | $0 | -$166M |
| 2024 Q4 |
